Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=102"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=102

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02720094-75a50b74",
        "title": "Cabotegravir vs TDF/FTC: Number of Participants With Documented Incident HIV Infections in Step 2",
        "summary": "8 of 2114 against 37 of 2079; risk difference -1.4 points, 95% interval -2.1 to -0.8; NCT02720094, Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men",
        "record": "/library/comparisons/NCT02720094-75a50b74",
        "nct_id": "NCT02720094",
        "kind": "outcome",
        "participants": 4193,
        "risk_difference": {
          "value": -0.014012722621994145,
          "lower": -0.020906483606117996,
          "upper": -0.00792703023425435
        },
        "group_1": "8 of 2,114",
        "group_2": "37 of 2,079",
        "difference": "-1.4 points",
        "interval": "-2.1 to -0.8",
        "trial_title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men"
      },
      {
        "id": "NCT01703208-477b8423",
        "title": "Omarigliptin 25 mg vs Placebo: Number of Participants With an Event of Stroke (Fatal and Non-fatal)",
        "summary": "32 of 2092 against 34 of 2100; risk difference -0.1 points, 95% interval -0.9 to 0.7; NCT01703208, A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)",
        "record": "/library/comparisons/NCT01703208-477b8423",
        "nct_id": "NCT01703208",
        "kind": "outcome",
        "participants": 4192,
        "risk_difference": {
          "value": -0.0008941090776654823,
          "lower": -0.008641230101680646,
          "upper": 0.006828865077302281
        },
        "group_1": "32 of 2,092",
        "group_2": "34 of 2,100",
        "difference": "-0.1 points",
        "interval": "-0.9 to 0.7",
        "trial_title": "A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=103",
  "request_id": "onA2Iis_SFDOIL93"
}